CTCE 9908
Purity: ≥95%
Biological Activity
CTCE 9908 is a CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol (Cat. No. 1097). Enhances the efficacy of docetaxel (Cat. No. 4056) in a mouse model.Technical Data
(Modifications: Amide bridge = 9-8*, Lys-9 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors
A Van Hout, T D'huys, M Oeyen, D Schols, T Van Loy
PLoS ONE, 2017;12(4):e0176057. -
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.
Kwong et al.
Mol.Cancer Ther., 2009;8:1893 -
The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells.
Faber et al.
J.Biomed.Biotechnol., 2007;2007:26065 -
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or doce. in a transgenic mouse model.
Hassan et al.
Int.J.Cancer., 2011;129:225
Product Datasheets
Citation for CTCE 9908
The citations listed below are publications that use Tocris products. Selected citations for CTCE 9908 include:
1 Citation: Showing 1 - 1
-
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
Authors: Ludger Et al.
Sci Rep 2020;10:16036
FAQs
No product specific FAQs exist for this product, however you may
View all Peptide FAQsReviews for CTCE 9908
There are currently no reviews for this product. Be the first to review CTCE 9908 and earn rewards!
Have you used CTCE 9908?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
